Browsing by Author "Necati DURU"
Now showing 1 - 2 of 2
- Results Per Page
- Sort Options
Review Citation Count: 0The Effect of Ranibizumab and Dexamethasone Implant Treatment on Retinal Nerve Fiber Layer Thickness in Eyes with Branch Retinal Vein Occlusion(2021) Orhan ALTUNEL; Necati DURU; Burhan BAŞKAN; Hasan Basri ARİFOĞLU; Bedirhan ALABAY; Mustafa ATAŞPurpose: To investigate the effects of intravitreal ranibizumab and dexamethasone implant treatments on the retinal nerve fiber layer (RNFL) thickness in patients with branch retinal vein occlusion (BRVO). Materials and Methods: Fifty-three patients with macular edema secondary to BRVO were enrolled in this retrospective study. These studygroup patients were divided into two groups. Group 1 consisted of 29 patients treated with intravitreal ranibizumab, and Group 2 consisted of 24 patients treated with intravitreal dexamethasone implants. The control group was the 53 normal fellow eyes of these patients. Peripapillary RNFL thickness was evaluated by using optical coherence tomography at baseline and during 12 months after treatment in both groups. Also, the RNFL thickness of the affected area in eyes with BRVO was compared with those of the normal fellow eyes. Results: The average, superior-temporal and inferior-temporal quadrant peripapillary RNFL thicknesses in eyes with BRVO were significantly decreased at 12 months after treatment in two groups. The RNFL thicknesses in the affected areas in Group 1 and Group 2 were significantly thinner than that of the control fellow eyes at 12 months (p=0.04 and p=0.02, respectively). Also, there was no significant difference in terms of RNFL thickness in the affected area between the groups at six and 12 months (p=0.808, p=0.356, respectively). Conclusion: Our study revealed that the average, superior-temporal and inferior-temporal RNFL thickness in the eyes of BRVO was reduced at 12 months. We suggest that RNFL thinning is due to the natural course of the disease in BRVO. Key words: Ranibizumab, branch retinal vein occlusion, Dexamethasone implant, retinal nerve fiber layer.Article Citation Count: 0Monocyte to High-Density Lipoprotein Ratio: A Novel Inflammation Marker Related to Diabetic Retinopathy(2020) Derya ŞAHİN; Işıl ÇAKIR; Necati DURU; Emine PANGAL; Nahide GÜNAY; Hasan Basri ARİFOĞLU; Gökçen ALICI SERTObjective: The most common microvascular complication of diabetes is diabetic retinopathy (DR). A new and recentlyemerged marker of oxidative stress and inflammation is monocyte to high-density lipoprotein cholesterol ratio (MHR).Platelet to lymphocyte ratio (PLR) and neutrophil to lymphocyte ratio (NLR) have also been shown as they are biomarkers ofsystemic inflammation in various diseases. The present study aims to assess MHR, its predictive value and relations betweenother inflammation markers in DR patients.Materials and Methods: Sixty-eight patients with DR, fifty-four DM patients without DR and forty-two control subjectswere included in this study. Complete blood count, lipoprotein and uric acid levels were recorded. MHR was calculated.Results: MHR, NLR and PLR were statistically significantly higher in DR group than DM without DR group (p=0.008,p=0.042, p=0.003, respectively). Then, receiver operating characteristic (ROC) curve analysis was performed and pointedthat MHR predicted DR using a cut-off level of 0.0156 with 63% sensitivity and 76% specificity.Conclusion: In this study, we investigated MHR in DR patients and its relationship with other inflammatory markers,lipoproteins and uric acid. We suggested that an elevated admission of MHR may be of benefit to detect DR and to determinethe CVD risk of these patients.